Navigation Links
Akrimax Pharmaceuticals Announces Manufacturing Partnership

Signs Agreement with Global Healthcare Company

ROUSES POINT, N.Y., Jan. 6 /PRNewswire/ -- Akrimax Pharmaceuticals, LLC announced today a manufacturing agreement for the production of pharmaceutical products for a global company beginning in 2009. Akrimax was selected from several potential partners in a competitive process.

Akrimax President Alan L. Rubino said: "This agreement further validates Akrimax's decision to acquire the Rouses Point facility which possesses diverse manufacturing and packaging capabilities, and a spotless regulatory and safety record. We are pleased to announce this development as we are ahead of our planned schedule of bringing in new manufacturing partnerships to our Rouses Point facility."

Rubino also said: "Our contract manufacturing partnership enhances our strategic plan and showcases the quality of our people and our ability to execute at this facility. We are proving every day that Made in America pharmaceutical manufacturing is good business for our partners because of our high-quality manufacturing, competitive value and excellent track record with the FDA."

About Akrimax

Akrimax Pharmaceuticals, LLC is a privately-held, fully-integrated next-generation specialty pharmaceutical company concentrated on acquiring marketed products and developing select late-stage products to address disease states related to "metabolic syndrome." The company also owns a world-class plant in Rouses Point, NY with a highly skilled workforce. Akrimax manufactures its own products and develops select manufacturing partnerships. The plant encompasses 67.6 acres with 38 buildings, offering approximately 1 million sq. feet of manufacturing and packaging space. Akrimax was formed in 2007 and purchased the Rouses Point plant from Wyeth in January 2008.

Based in Cranford, NJ, Akrimax pursues unsurpassed quality in the development, production, manufacturing, distribution, and commercialization of a full range of top-quality pharmaceutical products. Akrimax currently markets Inderal(R) LA and LoOvral(R) branded products and operates the manufacturing facility in conjunction with Wyeth during a transition period that runs through 2009.

    For more information
    Timothy Soule:
    Kevin Ellis: Kimbell Sherman Ellis: 800-498-5390 ext. 107:

SOURCE Akrimax Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
3. AUDIO from Medialink and Solvay Pharmaceuticals: New Initiative Urges Women to Address Mens Health this New Year
4. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
5. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
6. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
7. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
8. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
9. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
10. Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis
11. SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth Pharmaceuticals
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... additions to its industry-leading suite of automated breast density assessment and enterprise ... (RSNA) meeting, November 29-December 4, 2015 (South Hall booth #2377). Volpara’s quantitative ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Kreithen”), one of the leading plastic surgery practices in Florida, is proud to ... to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. ...
(Date:11/30/2015)... ... 30, 2015 , ... The successful filing of an Investigational New Drug application ... important to this key industry segment, Regis Technologies has decided to sponsor and participate ... at 11am EST. , Federal law does not allow new drugs to cross state ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... assets of DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. ... programming and technical experience available within DataTrade to extend the services currently provided ...
(Date:11/30/2015)... ... November 30, 2015 , ... GKhair & Tibolli team members and ... Beauty Show held on November 8th and 9th at the Puerto Rico Convention Center, ... artists, renowned beauticians and top of the line fashion journalists. The San Juan Beauty ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 Cumberland Pharmaceuticals (CPIX), today announced that ... on December 3, 2015. TIME: 3:15p.m. ET ... ET LINK: --> DATE: ... --> --> ... are invited to ask the company questions in real-time - ...
(Date:11/30/2015)... -- Varian Medical Systems (NYSE: VAR ) has signed a ... Hospitals Group, the largest hospital chain in India ... in the country. The MoU was signed by Dr. K. ... Kakkar , Varian,s India managing director, in ... , Varian intends to deploy its Access to Care program by ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
Breaking Medicine Technology: